Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Proc Natl Acad Sci U S A ; 118(35)2021 08 31.
Article de Anglais | MEDLINE | ID: mdl-34452998

RÉSUMÉ

Efforts to improve estrogen receptor-α (ER)-targeted therapies in breast cancer have relied upon a single mechanism, with ligands having a single side chain on the ligand core that extends outward to determine antagonism of breast cancer growth. Here, we describe inhibitors with two ER-targeting moieties, one of which uses an alternate structural mechanism to generate full antagonism, freeing the side chain to independently determine other critical properties of the ligands. By combining two molecular targeting approaches into a single ER ligand, we have generated antiestrogens that function through new mechanisms and structural paradigms to achieve antagonism. These dual-mechanism ER inhibitors (DMERIs) cause alternate, noncanonical structural perturbations of the receptor ligand-binding domain (LBD) to antagonize proliferation in ER-positive breast cancer cells and in allele-specific resistance models. Our structural analyses with DMERIs highlight marked differences from current standard-of-care, single-mechanism antiestrogens. These findings uncover an enhanced flexibility of the ER LBD through which it can access nonconsensus conformational modes in response to DMERI binding, broadly and effectively suppressing ER activity.


Sujet(s)
Tumeurs du sein/traitement médicamenteux , Antagonistes des oestrogènes/composition chimique , Antagonistes des oestrogènes/pharmacologie , Récepteur alpha des oestrogènes/antagonistes et inhibiteurs , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Cristallographie aux rayons X , Femelle , Humains , Liaison aux protéines , Conformation des protéines , Relation structure-activité , Cellules cancéreuses en culture
2.
Nat Chem Biol ; 17(3): 307-316, 2021 03.
Article de Anglais | MEDLINE | ID: mdl-33510451

RÉSUMÉ

Glucocorticoids display remarkable anti-inflammatory activity, but their use is limited by on-target adverse effects including insulin resistance and skeletal muscle atrophy. We used a chemical systems biology approach, ligand class analysis, to examine ligands designed to modulate glucocorticoid receptor activity through distinct structural mechanisms. These ligands displayed diverse activity profiles, providing the variance required to identify target genes and coregulator interactions that were highly predictive of their effects on myocyte glucose disposal and protein balance. Their anti-inflammatory effects were linked to glucose disposal but not muscle atrophy. This approach also predicted selective modulation in vivo, identifying compounds that were muscle-sparing or anabolic for protein balance and mitochondrial potential. Ligand class analysis defined the mechanistic links between the ligand-receptor interface and ligand-driven physiological outcomes, a general approach that can be applied to any ligand-regulated allosteric signaling system.


Sujet(s)
Anti-inflammatoires/pharmacologie , Transporteur de glucose de type 4/génétique , Amyotrophie/traitement médicamenteux , Récepteurs aux glucocorticoïdes/composition chimique , Transduction du signal/effets des médicaments et des substances chimiques , Cellules A549 , Régulation allostérique , Animaux , Anti-inflammatoires/synthèse chimique , Lignée de cellules transformées , Régulation de l'expression des gènes , Glucose/métabolisme , Transporteur de glucose de type 4/métabolisme , Humains , Lipopolysaccharides/administration et posologie , Mâle , Potentiel de membrane mitochondriale/effets des médicaments et des substances chimiques , Souris , Souris de lignée C57BL , Mitochondries/effets des médicaments et des substances chimiques , Mitochondries/métabolisme , Fibres musculaires squelettiques/effets des médicaments et des substances chimiques , Fibres musculaires squelettiques/métabolisme , Fibres musculaires squelettiques/anatomopathologie , Amyotrophie/induit chimiquement , Amyotrophie/génétique , Amyotrophie/métabolisme , Myoblastes/effets des médicaments et des substances chimiques , Myoblastes/métabolisme , Rats , Récepteurs aux glucocorticoïdes/génétique , Récepteurs aux glucocorticoïdes/métabolisme , Relation structure-activité
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...